Oikonomou Theodora, Goulis Ioannis, Soulaidopoulos Stergios, Karasmani Areti, Doumtsis Petros, Tsioni Konstantina, Mandala Eudokia, Akriviadis Evangelos, Cholongitas Evangelos
4 Department of Internal Medicine, Hippokration General Hospital, Medical School Aristotle University of Thessaloniki, Greece.
Ann Gastroenterol. 2017;30(2):217-224. doi: 10.20524/aog.2016.0112. Epub 2016 Dec 8.
Studies in patients with decompensated cirrhosis showed a correlation between serum ferritin levels and patients' prognosis. Besides, red blood cell distribution width (RDW) and mean platelet volume (MPV) have been associated with the severity of hepatic function. The aim of this study was to evaluate the prognostic impact of serum ferritin and RDW/MPV in the outcome [survival, death, or liver transplantation (LT)] of patients with stable decompensated cirrhosis.
Consecutive adult patients with stable decompensated cirrhosis admitted to our department between September 2010 and February 2016 were included. Serum ferritin, RDW and MPV were recorded in every patient. They were followed up and their outcome (alive, death, or LT) was evaluated.
192 consecutive patients with stable decompensated cirrhosis (142 men, age 54.2±12 years); at the end of follow up [12 (range: 1-64) months] 62 patients remained alive and 130 died or underwent LT. In multivariate analysis, serum ferritin (HR 1.001, 95%CI 1.00-1.002, P=0.005) and GFR (HR 0.96, 95%CI 0.92-0.99, P=0.035) were the only independent factors significantly associated with the outcome. Ferritin had low discriminative ability (AUC: 0.61) to the outcome yielding a sensitivity and specificity of 85.3% and 44.2%, respectively, at the best cut-off point (>55 ng/mL), while patients with ferritin >55 ng/mL (n=145) had a worse outcome compared to those with ferritin ≤55 ng/mL (n=47) (log rank P=0.001). RDW and MPV were not associated with the outcome.
High serum ferritin, but not RDW/MPV, is associated with worse outcome in patients with established decompensated cirrhosis. However, further studies are needed to elucidate better this issue.
对失代偿期肝硬化患者的研究表明,血清铁蛋白水平与患者预后之间存在相关性。此外,红细胞分布宽度(RDW)和平均血小板体积(MPV)与肝功能严重程度相关。本研究旨在评估血清铁蛋白和RDW/MPV对稳定失代偿期肝硬化患者结局(生存、死亡或肝移植(LT))的预后影响。
纳入2010年9月至2016年2月期间我院收治的连续性成年稳定失代偿期肝硬化患者。记录每位患者的血清铁蛋白、RDW和MPV。对他们进行随访并评估其结局(存活、死亡或LT)。
192例连续性稳定失代偿期肝硬化患者(142例男性,年龄54.2±12岁);随访结束时[12(范围:1 - 64)个月],62例患者存活,130例死亡或接受了LT。多因素分析显示,血清铁蛋白(HR 1.001,95%CI 1.00 - 1.002,P = 0.005)和肾小球滤过率(GFR)(HR 0.96,95%CI 0.92 - 0.99,P = 0.035)是与结局显著相关的仅有的独立因素。铁蛋白对结局的判别能力较低(AUC:0.61),在最佳截断点(>55 ng/mL)时,敏感性和特异性分别为85.3%和44.2%,而铁蛋白>55 ng/mL的患者(n = 145)与铁蛋白≤55 ng/mL的患者(n = 47)相比结局更差(对数秩检验P = 0.001)。RDW和MPV与结局无关。
血清铁蛋白水平升高而非RDW/MPV与已确诊的失代偿期肝硬化患者的不良结局相关。然而,需要进一步研究以更好地阐明这一问题。